###begin article-title 0
LRP1 Functions as an Atheroprotective Integrator of TGFbeta and PDGF Signals in the Vascular Wall: Implications for Marfan Syndrome
###end article-title 0
###begin p 1
Conceived and designed the experiments: JH PB. Performed the experiments: PB WL YT RM. Analyzed the data: RA JH PB JA. Contributed reagents/materials/analysis tools: RA WL YT RM JA. Wrote the paper: JH PB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
The multifunctional receptor LRP1 controls expression, activity and trafficking of the PDGF receptor-beta in vascular smooth muscle cells (VSMC). LRP1 is also a receptor for TGFbeta1 and is required for TGFbeta mediated inhibition of cell proliferation.
###end p 3
###begin title 4
Methods and Principal Findings
###end title 4
###begin p 5
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 316 317 310 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
We show that loss of LRP1 in VSMC (smLRP-) in vivo results in a Marfan-like syndrome with nuclear accumulation of phosphorylated Smad2/3, disruption of elastic layers, tortuous aorta, and increased expression of the TGFbeta target genes thrombospondin-1 (TSP1) and PDGFRbeta in the vascular wall. Treatment of smLRP1- animals with the PPARgamma agonist rosiglitazone abolished nuclear pSmad accumulation, reversed the Marfan-like phenotype, and markedly reduced smooth muscle proliferation, fibrosis and atherosclerosis independent of plasma cholesterol levels.
###end p 5
###begin title 6
Conclusions and Significance
###end title 6
###begin p 7
Our findings are consistent with an activation of TGFbeta signals in the LRP1-deficient vascular wall. LRP1 may function as an integrator of proliferative and anti-proliferative signals that control physiological mechanisms common to the pathogenesis of Marfan syndrome and atherosclerosis, and this is essential for maintaining vascular wall integrity.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 653 656 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 657 660 654 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Takayama1">[3]</xref>
###xml 667 668 664 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1309 1312 1300 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 669 673 <span type="species:ncbi:10090">mice</span>
Cholesterol-induced atherosclerosis is a major cause of morbidity and mortality in Western societies. In the liver, the low-density lipoprotein (LDL) receptor functions in concert with another LDL receptor family member, the LDL receptor-related protein 1 (LRP1), in removing cholesterol carrying lipoprotein particles from the bloodstream. However, in the smooth muscle cells of the artery wall LRP1 acts through a different, cholesterol-independent mechanism in the maintenance of vascular wall integrity and atherosclerosis prevention, which relies in part on the ability of LRP1 to regulate the activity and subcellular trafficking of the PDGFRbeta [1]-[3]. SmLRP- mice that lack LRP1 in vascular smooth muscle cells show thickening of the muscular layer and greatly increased susceptibility to atherosclerotic lesion development, even at low plasma cholesterol levels. On a high cholesterol diet, lesion development and progression is dramatically accelerated, resulting in the occlusion of major arteries within 2 months of cholesterol feeding. Pharmacologic inhibition of PDGFRbeta signaling reduced both lesion progression and smooth muscle over-proliferation, suggesting that the abnormal activation of PDGFRbeta is at least in part responsible for the accelerated lesion development and progression [1].
###end p 9
###begin p 10
###xml 146 149 146 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boileau1">[4]</xref>
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Dietz1">[5]</xref>
###xml 392 395 389 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Kaartinen1">[6]</xref>
###xml 431 434 428 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Dietz2">[7]</xref>
###xml 436 439 433 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Pereira1">[8]</xref>
###xml 614 617 608 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boileau1">[4]</xref>
###xml 619 622 613 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Dietz1">[5]</xref>
###xml 624 627 618 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Neptune1">[9]</xref>
###xml 743 747 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Loeys1">[10]</xref>
###xml 748 752 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Pannu1">[12]</xref>
###xml 858 862 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Loeys1">[10]</xref>
On the other hand, the characteristic disruption of elastic layers, elongation of the aortas and aneurysms are hallmarks of Marfan syndrome (MFS) [4], [5], an autosomal dominant genetic disease. MFS is caused by loss of function mutations in fibrillin-1, a microfibrillar protein that coats the surface of elastic fibers where it binds and immobilizes the TGFbeta large latency complex (LLC) [6]. Haploinsufficiency of fibrillin-1 [7], [8] markedly changes the extracellular targeting, sequestration and turnover of latent TGFbeta, resulting in pronounced activation of the growth factor and the signaling pathway [4], [5], [9]. A phenotypically similar Marfan-like syndrome is caused by loss of function mutations in TGFbeta receptors 1 or 2 [10]-[12], which nevertheless result in a paradoxical activation of the pathway and nuclear accumulation of pSmad2 [10]. Thus, abnormal activation of TGFbeta signaling appears to be a common feature of Marfan and Marfan-like disorders.
###end p 10
###begin p 11
###xml 281 285 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Huang1">[13]</xref>
###xml 287 291 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Tseng1">[14]</xref>
###xml 397 401 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Battegay1">[15]</xref>
###xml 402 406 384 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Taylor1">[19]</xref>
###xml 571 575 550 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Jechlinger1">[20]</xref>
###xml 606 610 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Bruna1">[21]</xref>
###xml 716 720 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Igarashi1">[16]</xref>
###xml 722 726 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Fan1">[22]</xref>
###xml 797 801 773 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Takekawa1">[23]</xref>
###xml 873 877 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Crawford1">[24]</xref>
###xml 879 883 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Ribeiro1">[25]</xref>
###xml 957 961 930 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Orr1">[26]</xref>
###xml 1350 1351 1317 1318 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1357 1360 1324 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 1352 1356 <span type="species:ncbi:10090">mice</span>
Recently, LRP1 was reported to be identical to TGFbetaR(V), which is coexpressed together with TGFbeta receptors I, II and III. LRP1/TGFbetaR(V) is required for mediating the growth inhibitory response of TGFbeta, in conjunction with Smad2/3 signaling through TGFbetaR(I) and (II) [13], [14]. TGFbeta1 can induce the expression of connective tissue growth factor (CTGF), PDGF-B and PDGF receptors [15]-[19]. Activation of a PDGF/PDGFR autocrine loop by TGFbeta mediates epithelial-mesenchymal transition and constitutes a crucial mechanism that enhances tumor metastasis [20] and the malignancy of gliomas [21]. All of these proteins are not only ligands for LRP1, they also promote smooth muscle cell proliferation [16], [22]. Furthermore, TSP1, another ligand for LRP1 and a TGFbeta target gene [23], directly mediates the conversion of latent TGFbeta to the active form [24], [25] and TSP1 binding to an LRP1/calreticulin complex regulates cell adhesion [26]. Thus, LRP1 is tightly involved in the control of growth regulating signaling processes that involve TGFbeta, PDGF, and their receptors. This prompted us to investigate, whether abnormal activation of TGFbeta signaling could be responsible for the striking disruption of the elastic fiber network, fibrosis, and accelerated atherosclerotic lesion development in the vascular wall of smLRP- mice [1].
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Activation of TGFbeta signaling in LRP1-deficient VSMC
###end title 13
###begin p 14
###xml 492 493 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 522 523 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 540 548 528 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g001">Figure 1</xref>
###xml 634 635 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 651 652 636 637 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
Vascular wall fibrosis, disruption of elastic layers, and tortuousity of the aorta were suggestive of abnormal TGFbeta signaling in smLRP-deficient mice. To obtain further evidence for the presence of increased TGFbeta activity, we used immunohistochemistry to visualize the levels of TGFbeta1 and TSP1, as well as the phosphorylated forms of Smad-1 and Smad-2, the intracellular mediators of TGFbeta family signals, in aortas from cholesterol-fed, LDL receptor deficient mice expressing (LRP+) or not expressing LRP1 (LRP-) in their VSMC (Figure 1). Expression of TSP-1, a direct TGFbeta1 target gene, was strikingly increased in LRP- compared to LPR+ aortas (Panels a and b), whereas total TGFbeta1 immunoreactivity was slightly reduced (Panels c and d), consistent with an increased activation and turnover of matrix-associated TGFbeta.
###end p 14
###begin p 15
###xml 229 233 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Habashi1">[27]</xref>
###xml 235 239 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-RuizOrtega1">[28]</xref>
TGFbeta1 and other TGFbeta family members, as well as angiotensin II are prominent inducers of Smad2-dependent target gene transcription, resulting in collagen deposition and disruption of the elastic layers in the vascular wall [27], [28]. Prominent accumulation of nuclear phosphorylated Smad2/3 (pSmad2/3) was found in VSMC in the absence of LRP1 (Panels e and f). This effect was specific for Smad2, which is the target of TGFbeta signals, but not for Smad1, which responds to signals elicited by bone morphogenic proteins (BMPs). pSmad1 was not significantly elevated in the absence of LRP1 (Panels g and h). These findings, taken together with the molecular properties of LRP1, make it likely that TGFbeta signaling in VSMC is indeed selectively increased in the absence of LRP1.
###end p 15
###begin title 16
Rosiglitazone reduces TGFbeta signals in vitro and in vivo
###end title 16
###begin p 17
###xml 128 132 121 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Fu1">[29]</xref>
###xml 134 138 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Ghosh1">[30]</xref>
###xml 181 185 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Li1">[31]</xref>
###xml 786 794 766 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g002">Figure 2</xref>
###xml 410 414 <span type="species:ncbi:10090">mice</span>
###xml 657 662 <span type="species:ncbi:9606">human</span>
###xml 675 681 <span type="species:ncbi:10090">murine</span>
PPARgamma agonists of the thiazolidinedione class have been reported to inhibit TGFbeta signaling, CTGF expression and fibrosis [29], [30], and they also can reduce atherosclerosis [31]. We therefore decided to test, whether activation of PPARgamma by rosiglitazone, a compound of this class that is in clinical use, might result in reduced nuclear accumulation of pSmad2 and suppression of atherosclerosis in mice lacking LRP1. We first examined the effect of rosiglitazone on PDGFRbeta and pSmad2/3 levels in cultured cells in vitro. While TGFbeta1 only moderately elevated PDGFRbeta expression in vitro, it markedly increased pSmad2/3 levels in cultured human VSMC and in murine fibroblasts. This increase was significantly blunted when the cells were pretreated with rosiglitazone (Figure 2).
###end p 17
###begin p 18
###xml 182 183 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 193 194 190 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 295 303 292 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g003">Figure 3</xref>
###xml 357 360 354 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 511 512 505 506 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 546 547 540 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 800 801 791 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 901 904 892 895 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
To test, whether rosiglitazone was able to correct the abnormal accumulation of pSmad2/3 levels and activation of PDGFRbeta signaling in smLRP deficient animals in vivo, we fed smLRP+ and smLRP- animals a cholesterol-rich diet that either contained or did not contain rosiglitazone for 5 weeks (Figure 3). Aortic extracts were prepared as described earlier [1] and analyzed by immunoblotting (Panel A). Rosiglitazone treatment (lane 3) significantly reduced the elevated pSmad2/3, PDGFRbeta and pErk1/2 in smLRP- aortas (lane 2) compared to smLRP+ controls (lane 1). We verified this result by immunofluorescence staining of aortas (Panel B). Rosiglitazone treatment (Panels c, f, i) abolished the increased nuclear pSmad2/3, overexpression of PDGFRbeta, and the increased pErk1/2 levels in the smLRP- animals (Panels b, e, h). As had been shown previously using the tyrosine kinase inhibitor Gleevec [1], rosiglitazone treatment also considerably improved the integrity of the elastic layers (Panel C).
###end p 18
###begin title 19
###xml 47 48 47 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Rosiglitazone prevents atherosclerosis in smLRP- mice
###end title 19
###begin p 20
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Li1">[31]</xref>
###xml 318 319 314 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 498 513 490 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g004">Figure 4A and C</xref>
###xml 623 632 615 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g004">Figure 4B</xref>
###xml 796 807 788 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g004">Figure 4D&#8211;F</xref>
###xml 69 73 <span type="species:ncbi:10090">mice</span>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
Thiazolidinediones have been reported to protect male LDLR-deficient mice from developing atherosclerotic lesions [31], coinciding with reductions in gelatinase and TNFalpha expression. To test whether blockade of the increased Smad activation by rosiglitazone would also reduce the marked atherosclerosis in the smLRP- mice, we quantitatively examined the aortas from the atherogenic diet-fed mice. Atherosclerotic lesion areas were significantly reduced in the presence of the PPARgamma agonist (Figure 4A and C), and the striking thickening and fibrosis of the LRP deficient vessel wall was almost completely abolished (Figure 4B). Importantly, these changes were not caused by or secondary to any effect of rosiglitazone on the plasma lipoprotein profile, triglyceride or cholesterol levels (Figure 4D-F).
###end p 20
###begin title 21
Discussion
###end title 21
###begin p 22
The findings we have presented here reveal a novel mechanism by which the multifunctional receptor LRP1 functions as an integrator of two distinct cellular signaling pathways in the vascular wall. They also suggest a functional relationship between the molecular events that underlie MFS, the formation of aneurysms and atherosclerosis. Our results show that LRP1 controls Smad2/3-as well as PDGF-dependent signaling in VSMC in a coordinated fashion and by distinct mechanisms.
###end p 22
###begin p 23
###xml 62 65 59 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher2">[2]</xref>
###xml 67 71 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Loukinova1">[32]</xref>
###xml 189 192 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 194 197 188 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Takayama1">[3]</xref>
###xml 414 418 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Kretzschmar1">[33]</xref>
###xml 650 654 635 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Jechlinger1">[20]</xref>
###xml 698 702 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Bruna1">[21]</xref>
LRP1 is a target of PDGFRbeta-dependent Src kinase activation [2], [32] and we showed earlier that loss of LRP1 expression in VSMCs results in increased PDGFRbeta expression and activation [1], [3]. In the present study we have demonstrated, that loss of LRP1 expression also results in increased Smad2/3-dependent signaling in VSMCs. A potent inducer of Smad2 phosphorylation and nuclear translocation is TGFbeta [33]. Moreover, induction of PDGF as well as PDGFRbeta expression in response to TGFbeta stimulation has been recognized as an important component of epithelial-mesenchymal transition, a process that underlies metastasis of some tumors [20] and increases the aggressiveness of others [21]. Our results show that increased pSmad2/3 signaling in the LRP1-deficient vascular wall results in increased PDGFRbeta expression and activation, making it likely that TGFbeta is directly involved.
###end p 23
###begin p 24
###xml 58 62 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Huang1">[13]</xref>
###xml 113 117 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Liu1">[34]</xref>
###xml 517 521 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Emonard1">[35]</xref>
###xml 522 526 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Herz1">[37]</xref>
###xml 617 625 596 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g001">Figure 1</xref>
###xml 631 634 610 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 696 700 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Crawford1">[24]</xref>
###xml 702 706 678 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Ribeiro1">[25]</xref>
###xml 708 712 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Yu1">[38]</xref>
###xml 918 919 891 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 928 936 901 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g001">Figure 1</xref>
###xml 1342 1348 <span type="species:ncbi:9606">humans</span>
Furthermore, LRP1/TGFbetaR(V), can directly bind TGFbeta1 [13], as well as enter into a complex with TGFbetaR(I) [34]. By binding and endocytosis of the active growth factor and also by sequestering TGFbetaR(I) away from TGFbetaR(II), LRP1 is in a central position where it can suppress the normal mode of TGFbeta signaling and Smad2/3 activation through the TGFbetaR(I)/R(II) complex. In addition, LRP1 mediates the endocytosis of TSP1 as well as several matrix metalloproteinases (MMP) from the extracellular space [35]-[37], and TSP1 as well as active MMP2 and MMP9 levels are increased in smLRP deficient aortas (Figure 1, and [1]). TSP1 and MMPs potently and independently activate TGFbeta1 [24], [25], [38]. Loss of smLRP would thus be predicted to activate TGFbeta/Smad signaling in VSCM by multiple independent mechanisms, and this is consistent with the dramatically increased nuclear pSmad2/3 levels in smLRP- aortas (Figure 1). The resulting disruption of elastic layers, vascular fibrosis, elongation and distension of the aorta, and high incidence of aortic aneurysms directly support the pivotal role of TGFbeta signaling in the pathogenesis of MFS and reveal LRP1 as a critical regulator of this pathway in vivo. As such, LRP1 could conceivably contribute as a genetic modifier to the variable severity of expression of MFS in humans.
###end p 24
###begin p 25
###xml 127 128 124 125 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 286 290 272 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Fu1">[29]</xref>
###xml 292 296 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Law1">[39]</xref>
###xml 298 302 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Zirlik1">[40]</xref>
###xml 752 756 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Habashi1">[27]</xref>
We have further demonstrated the importance of TGFbeta signaling through pharmacological intervention and reversal of the smLRP- phenotype with the PPARgamma agonist rosiglitazone. Activation of PPARgamma with thiazolidinediones potently inhibits TGFbeta signaling in vitro and in vivo [29], [39], [40]. The striking effect of rosiglitazone on the nuclear accumulation of pSmad2/3 and the near complete reversal of the aortic wall thickening and fibrosis, and prevention of atherosclerotic lesion progression confirm the central importance of TGFbeta pathway activation for this phenotype. PPARgamma agonists might thus complement and enhance the potential therapeutic use of the angiotensin II type 1 receptor blocker Losartan in the treatment of MFS [27].
###end p 25
###begin p 26
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 116 119 116 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 263 267 259 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Li1">[31]</xref>
###xml 383 386 379 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 424 425 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 638 639 631 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 878 881 865 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 934 942 921 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g002">Figure 2</xref>
###xml 947 948 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g003">3</xref>
###xml 950 954 937 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Battegay1">[15]</xref>
###xml 956 960 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Jechlinger1">[20]</xref>
###xml 962 966 949 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Gotzmann1">[41]</xref>
###xml 1071 1074 1055 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Takayama1">[3]</xref>
###xml 1394 1397 1375 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Takayama1">[3]</xref>
###xml 1544 1552 1519 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0000448-g005">Figure 5</xref>
###xml 1643 1644 1618 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 234 238 <span type="species:ncbi:10090">mice</span>
###xml 426 430 <span type="species:ncbi:10090">mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
Increased susceptibility to atherosclerosis is not a part of the MFS complex, but a striking feature of smLRP- mice [1]. Likewise, PPARgamma agonists are only partially effective against diet-induced atherosclerosis in LDLR deficient mice when LRP1 is functional [31]. By contrast, we have shown that rosiglitazone (this study) as well as the PDGFR tyrosine kinase inhibitor Gleevec [1] are highly potent in protecting smLRP- mice from atherosclerosis. Our findings thus suggest that abnormal activation of PDGFRbeta signaling, which has so far not been reported in MFS, is the major mediator of the increased atherosclerosis in the smLRP- mice, and that increased PDGFRbeta activity is brought about by two independent and synergistic mechanisms. First, activation of Smad/TGFbeta signals in the absence of LRP1 results in the disruption of elastic layers and a tortuous aorta [1], as well as increased expression of PDGF receptors (Figure 2 and 3) [15], [20], [41]. However, since LRP1 also controls PDGFRbeta activity and recycling at the level of the plasma membrane [3], loss of LRP1 in smooth muscle cells also results in a greatly increased mitogenic response, VSMC proliferation and the promotion of atherosclerotic lesion formation. This second event is prevented in MFS by the presence of LRP1, which suppresses the abnormal PDGFRbeta activation through a posttranslational mechanism [3]. Thus, rosiglitazone (as a Smad/TGFbeta antagonist) and Gleevec (as a PDGFRbeta inhibitor) act at different steps in a linear sequence of events (Figure 5) that result in a Marfan-like syndrome and culminate in extensive atherosclerosis in smLRP- artery walls.
###end p 26
###begin p 27
###xml 186 187 183 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 193 196 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 789 793 774 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Gao1">[42]</xref>
###xml 866 870 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-RuizOrtega1">[28]</xref>
###xml 979 983 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Habashi1">[27]</xref>
###xml 1513 1517 1489 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Morosetti1">[43]</xref>
###xml 188 192 <span type="species:ncbi:10090">mice</span>
###xml 948 953 <span type="species:ncbi:10090">mouse</span>
Nevertheless, blockade of PDGFRbeta signaling alone by administration of Gleevec was sufficient to reduce atherosclerotic lesion progression, as well as vascular wall thickness, in smLRP- mice [1], suggesting that signaling through this pathway is necessary for elastic layer disruption and wall thickening. This raises the possibility that PDGFRbeta signaling may be activated to some extent in the Marfan vessel wall, or alternatively the mere suppression of its baseline activity may be sufficient to normalize the vessel wall thickening that is initiated by increased TGFbeta activity. Consistent with an important role of PDGFRbeta in vascular thickening is a recent report that showed transphosphorylation of a truncated PDGFRbeta induced by the Angiotensin II type 1 receptor (AT1) [42], which can also activate Smad2-dependent signals independent of TGFbeta [28]. AT1 is inhibited by Losartan, a drug that also reduced wall thickening in a mouse model of Marfan syndrome [27]. Taken together, these findings indicate a critical role for Smad2-and AT1-dependent signaling mechanisms in Marfan and Marfan-like syndromes and identify PDGFRbeta as another important component of the pathogenic mechanism. Our findings also suggest that rosiglitazone, a clinically approved antidiabetic drug, may be useful for the treatment of vasculopathies that are caused by increased TGFbeta signaling, e.g. Marfan syndrome, as well as for the supportive treatment of certain malignancies, such as malignant glioblastomas [43].
###end p 27
###begin title 28
Materials and Methods
###end title 28
###begin title 29
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
Transgenic mice and diets
###end title 29
###begin p 30
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 97 98 97 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 102 111 102 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 141 142 141 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 149 150 149 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 353 354 353 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 383 392 383 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 397 400 397 400 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 411 412 411 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 226 231 <span type="species:ncbi:10090">Mouse</span>
###xml 232 235 <span type="species:ncbi:10116">Rat</span>
Homozygous LDL receptor (LDLR-/-) animals LRP deficient in vascular smooth muscle cells (SM22-Cre+;LRPflox/flox;LDLR-/-, referred to as smLRP- or LRP-) have been described previously [1] and were maintained on Teklad 6% (w/w) Mouse/Rat Diet 7002 from Harlan Teklad Premier Laboratory Diets (Madison, WI). Six weeks prior to sacrifice, 3-6 months old LRP- and littermate controls (LRPflox/flox;LDLR-/-, noted LRP+) were placed on a high-fat/high-cholesterol (Paigen) diet containing (21% (w/w) milk fat, 1.25% (w/w) cholesterol, 0.5% (w/w) cholic acid) and where indicated, the PPARgamma agonist rosiglitazone (Advantia(R), GlaxoSmithKline, 25mg/kg/day) was mixed into the diet. All animals used in the experiments were age and sex matched as closely as possible. All animal experiments were conducted according to procedures approved by the institutional Animal Care and Use Committee (IACUC) at UT Southwestern.
###end p 30
###begin title 31
Whole Aorta staining
###end title 31
###begin p 32
###xml 442 446 442 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Paigen1">[44]</xref>
After 4% paraformaldehyde cardiac perfusion, the whole aortas of animals from the different treated groups were carefully dissected from the heart to the iliac bifurcation. The vessels were rinsed in PBS and dissected to remove connective tissue and attached fat. The vessels were opened longitudinally and stained for lipids with Sudan IV. Atherosclerosis in the aortas was measured by quantitation of Sudan IV-positive lesions as described [44]. Whole mount preparations of the vessels were photographed and digitized. Sudan IV-positive lesions were delineated and analyzed using NIH Image software (NIH, Bethesda, Maryland, USA).
###end p 32
###begin title 33
Histology
###end title 33
###begin p 34
Aortic tissue was fixed over night with 4% paraformaldehyde and embedded in paraffin. Longitudinal and transverse sections (10 microm thick) were stained with hematoxylin-eosin under standard conditions.
###end p 34
###begin title 35
Immunofluorescence microscopy
###end title 35
###begin p 36
###xml 657 658 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 790 794 <span type="species:ncbi:9925">goat</span>
###xml 814 820 <span type="species:ncbi:9913">bovine</span>
###xml 892 898 <span type="species:ncbi:9986">rabbit</span>
###xml 1020 1026 <span type="species:ncbi:9986">rabbit</span>
###xml 1107 1113 <span type="species:ncbi:9913">bovine</span>
###xml 1223 1227 <span type="species:ncbi:9925">goat</span>
###xml 1233 1239 <span type="species:ncbi:9986">rabbit</span>
###xml 1356 1362 <span type="species:ncbi:9913">bovine</span>
Anesthetized wt and LRP KO mice were perfused through the left cardiac ventricle with warmed Hank's balanced salt solution (20 mM Hepes, pH 7.3) followed by the same solution containing 4% (w/v) paraformaldehyde. Aortas were removed and divided into small pieces. The tissue was immersion-fixed for an additional hour followed by treatment with a mixture of 60% (v/v) methanol, 10% (v/v) glacial acetic acid, 30% (v/v) inhibisol (1,1,1-trichloroethane) for 24 hours. Tissues were then embedded in paraffin. Paraffin sections (5 microm thick) were dewaxed in three changes of xylene (10 minutes each) and rehydrated in PBS. Sections were washed with 50 mM NH4Cl in PBS for 30 minutes and blocked by incubation for 1 h in TBS (10 mM Tris-HCl, pH 9.0, 150 mM NaCl) containing 10% (v/v) normal goat serum and 1% (w/v) bovine serum albumin. Samples were then incubated overnight at 4degreesC with rabbit antiserum raised against pSmad2 (1:200 dilution), PDGFRbeta (1:100 dilution), phospho-Erk (1:100 dilution), or preimmune rabbit serum (1:100 dilution). Sections were washed three times in TBS containing 0.1% bovine serum albumin, and bound primary antibody was detected by incubation for 2 h with Alexa-Fluor 488-conjugated goat anti-rabbit IgG (10 microg/ml, Molecular Probes, Eugene, OR). The tissues slides were washed three times in TBS containing 0.1% bovine serum albumin, rinsed with water, and mounted using Fluorescence Mounting Medium (DakoCytomation). Images were taken using a Leica TCS SP confocal microscope.
###end p 36
###begin title 37
Lipid and Lipoprotein analyses
###end title 37
###begin p 38
###xml 231 235 231 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Ishibashi1">[45]</xref>
At sacrifice, blood was collected by cardiac puncture and plasma was analyzed by FPLC on a Superose 6 column (Sigma Chemical Co.). Plasma and liver cholesterol content was determined spectrofluorimetrically as described previously [45].
###end p 38
###begin title 39
Western blotting
###end title 39
###begin p 40
###xml 510 513 503 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0000448-Boucher1">[1]</xref>
###xml 146 150 <span type="species:ncbi:9913">calf</span>
###xml 344 348 <span type="species:ncbi:9913">calf</span>
###xml 398 403 <span type="species:ncbi:9606">human</span>
MEF LRP deficient cells were seeded in 100 mm dishes (300 000 cells/dish) and grown to confluency in 10 ml DMEM supplemented with 10% (v/v) fetal calf serum and antibiotics. MEF LRP deficient cells were either left untreated or treated for the indicated times with the PPARgamma agonist rosiglitazone under reduced serum conditions (0.2% fetal calf serum), followed by stimulation with recombinant human TGFbeta1 (200 pM) for 0, 1.5, 3 or 6 hours. Whole cell lysates were then prepared as described previously [1], subjected to SDS polyacrylamide gel electrophoresis, transferred to poly(vinylidene) fluoride (PVDF) membranes (Millipore), and blotted for phospho-Smad2/3 or PDGF receptor-beta using specific antibodies directed against PDGF receptor-beta and phospho-Smad2/3 (S465/467), respectively (all from Upstate Biotechnology Incorporated, Lake Placid, NY). Proteins were detected using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech Inc, Piscataway, NJ).
###end p 40
###begin p 41
We thank Bob Hammer and Sally Comerford for helpful discussions and suggestions and Megan Davenport for excellent technical assistance.
###end p 41
###begin title 42
References
###end title 42
###begin article-title 43
LRP: role in vascular wall integrity and protection from atherosclerosis.
###end article-title 43
###begin article-title 44
Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae.
###end article-title 44
###begin article-title 45
Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFR beta).
###end article-title 45
###begin article-title 46
Molecular genetics of Marfan syndrome.
###end article-title 46
###begin article-title 47
Recent progress towards a molecular understanding of Marfan syndrome.
###end article-title 47
###begin article-title 48
Fibrillin controls TGF-beta activation.
###end article-title 48
###begin article-title 49
Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene.
###end article-title 49
###begin article-title 50
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1.
###end article-title 50
###begin article-title 51
Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome.
###end article-title 51
###begin article-title 52
A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2.
###end article-title 52
###begin article-title 53
Heterozygous TGFBR2 mutations in Marfan syndrome.
###end article-title 53
###begin article-title 54
Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections.
###end article-title 54
###begin article-title 55
Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1.
###end article-title 55
###begin article-title 56
LRP-1/TbetaR-V mediates TGF-beta1-induced growth inhibition in CHO cells.
###end article-title 56
###begin article-title 57
TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop.
###end article-title 57
###begin article-title 58
###xml 65 70 <span type="species:ncbi:9606">human</span>
Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair.
###end article-title 58
###begin article-title 59
Pathogenesis of fibrosis: role of TGF-beta and CTGF.
###end article-title 59
###begin article-title 60
TGFbeta1-dependent contraction of fibroblasts is mediated by the PDGFalpha receptor.
###end article-title 60
###begin article-title 61
Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads.
###end article-title 61
###begin article-title 62
Autocrine PDGFR signaling promotes mammary cancer metastasis.
###end article-title 62
###begin article-title 63
###xml 60 68 <span type="species:ncbi:9606">patients</span>
High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.
###end article-title 63
###begin article-title 64
Connective tissue growth factor (CTGF) stimulates vascular smooth muscle cell growth and migration in vitro.
###end article-title 64
###begin article-title 65
Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta.
###end article-title 65
###begin article-title 66
Thrombospondin-1 is a major activator of TGF-beta1 in vivo.
###end article-title 66
###begin article-title 67
The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta.
###end article-title 67
###begin article-title 68
Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly.
###end article-title 68
###begin article-title 69
###xml 59 64 <span type="species:ncbi:10090">mouse</span>
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome.
###end article-title 69
###begin article-title 70
TGF-beta signaling in vascular fibrosis.
###end article-title 70
###begin article-title 71
###xml 144 149 <span type="species:ncbi:9606">human</span>
Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3.
###end article-title 71
###begin article-title 72
Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
###end article-title 72
###begin article-title 73
###xml 124 128 <span type="species:ncbi:10090">mice</span>
Peroxisome proliferator-activated receptor {gamma} ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
###end article-title 73
###begin article-title 74
Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF.
###end article-title 74
###begin article-title 75
SMADs: mediators and regulators of TGF-beta signaling.
###end article-title 75
###begin article-title 76
###xml 128 132 <span type="species:ncbi:452646|species:ncbi:9666">mink</span>
Function of the type V transforming growth factor beta receptor in transforming growth factor beta-induced growth inhibition of mink lung epithelial cells.
###end article-title 76
###begin article-title 77
Low Density Lipoprotein Receptor-related Protein Mediates Endocytic Clearance of Pro-MMP-2{middle dot}TIMP-2 Complex through a Thrombospondin-independent Mechanism.
###end article-title 77
###begin article-title 78
The Low Density Lipoprotein Receptor-related Protein Modulates Levels of Matrix Metalloproteinase 9 (MMP-9) by Mediating Its Cellular Catabolism.
###end article-title 78
###begin article-title 79
LRP: a multifunctional scavenger and signaling receptor.
###end article-title 79
###begin article-title 80
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis.
###end article-title 80
###begin article-title 81
Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.
###end article-title 81
###begin article-title 82
###xml 75 80 <span type="species:ncbi:9606">human</span>
Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
###end article-title 82
###begin article-title 83
A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes.
###end article-title 83
###begin article-title 84
Angiotensin II stimulates phosphorylation of an ectodomain-truncated platelet-derived growth factor receptor-beta and its binding to class IA PI3K in vascular smooth muscle cells.
###end article-title 84
###begin article-title 85
###xml 145 150 <span type="species:ncbi:9606">human</span>
The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
###end article-title 85
###begin article-title 86
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Quantitative assessment of atherosclerotic lesions in mice.
###end article-title 86
###begin article-title 87
###xml 66 70 <span type="species:ncbi:10090">mice</span>
Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.
###end article-title 87
###begin title 88
Figures and Tables
###end title 88
###begin title 89
###xml 72 73 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
Increased pSmad2/3 expression and activation of TGFbeta signaling in LRP- mouse aorta.
###end title 89
###begin p 90
###xml 53 54 53 54 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 58 67 58 67 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 80 81 80 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 90 99 90 99 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">flox/flox</sup>
###xml 104 107 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
Longitudinal sections of abdominal aorta from SM22Cre+;LRPflox/flox;LDLR-/- (LRP-) and LRPflox/flox;LDLR-/- (LRP+) mice were stained with anti-TSP1, anti-TGFbeta1, anti-pSmad2/3 and anti-pSmad1 antibodies. Reduced LRP1 expression results in greatly enhanced expression of pSmad2/3 and its target gene, TSP1. By contrast, TGFbeta1 levels were slightly reduced, pSmad1 levels did not change. Bar in a indicates 20 microm.
###end p 90
###begin title 91
###xml 95 103 92 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Rosiglitazone treatment decreases expression of PDGFRbeta and activation of Smad2/3 (pSmad2/3) in vitro.
###end title 91
###begin p 92
###xml 106 109 103 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 169 171 166 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:9606">human</span>
Western blot analysis of activated Smad2/3 and PDGFRbeta in whole cell lysates from human VSMC and MEF LRP+/+ cells pretreated 0, 24 or 48 hours with rosiglitazone at 10-5M and then stimulated with human TGFbeta1 (200 pM) for 0, 1.5, 3 or 6 hours.
###end p 92
###begin title 93
###xml 47 48 44 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Activation of TGFbeta and PDGF signaling in LRP- mouse aortas are both prevented upon rosiglitazone treatment.
###end title 93
###begin p 94
###xml 179 180 179 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 204 205 204 205 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 151 156 <span type="species:ncbi:10090">Mouse</span>
Mice had been cholesterol-fed for 5 weeks in the absence (-Rosi) or presence (+Rosi) of rosiglitazone (GlaxoSmithKline, 25 mg/kg/day) before analysis. Mouse aortas expressing (LRP+) or not expressing (LRP-) LRP in VSMC were analyzed by western blot (Panel A) and immunohistochemistry (Panel B) for expression of PDGFRbeta (d-f), and for activation of Smad2/3 (pSmad2/3, a-c), and Erk1/2 (pErk1/2, g-i). Panel C shows elastic staining of corresponding sections and gaps in elastic fiber continuity (arrows). Bar indicates 40 microm, insert scale bar in B,a indicates 10 microm.
###end p 94
###begin title 95
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Quantitative analysis of atherosclerotic lesion size in aortas from cholesterol-fed mice with or without rosiglitazone treatment.
###end title 95
###begin p 96
###xml 50 51 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 65 66 65 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 544 545 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 559 560 559 560 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 599 600 599 600 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 746 747 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 764 765 760 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 892 893 886 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 978 979 972 973 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1004 1005 998 999 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1052 1053 1046 1047 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1080 1081 1074 1075 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1191 1192 1185 1186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1200 1201 1194 1195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 87 91 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">Mice</span>
###xml 767 771 <span type="species:ncbi:10090">mice</span>
###xml 779 783 <span type="species:ncbi:10090">mice</span>
###xml 1202 1206 <span type="species:ncbi:10090">mice</span>
###xml 1254 1258 <span type="species:ncbi:10090">mice</span>
(A) Aortas from 20-week-old mice that express (LRP+) of lack (LRP-) LRP in VSMC (n = 6 mice per group). Mice had been cholesterol-fed for 5 weeks in the absence (-Rosi) or presence (+Rosi) of rosiglitazone (GlaxoSmithKline, 25 mg/kg/day) before analysis. Aortae were stained en face with Sudan IV and arrows indicate lipid-laden (Sudan-positive) atherosclerotic lesions. Scale bar, 1.2 cm. (B) Histological analysis of thoracic aortas from animals cholesterol-fed in the absence or presence of rosiglitazone. Hematoxylin and eosin (a and b, LRP+; c and d, LRP-), and trichrome staining (e and f, LRP-) of longitudinal sections. Scale bar in a, 15 microm. (C) Quantitative analysis of atherosclerotic lesion size in aortas from cholesterol-fed LRP- and control (LRP+) mice (n = 5 mice per group) with and without rosiglitazone treatment. Values are expressed as mean+/-s.e.m. *, p<0.05 for LRP- treated versus untreated. (D) FPLC profile of plasma lipoproteins from untreated LRP- (filled squares) and LRP+ (opened squares) and rosiglitazone treated LRP- (filled triangles) and LRP+ (opened triangles). (E) Plasma triglycerides and (F) cholesterol from untreated and rosiglitazone treated LRP- and LRP+ mice. Values are expressed as mean+/-S.E.M. (n = 10 mice per group).
###end p 96
###begin title 97
Control of TGFbeta and PDGF signaling and protection of vascular wall integrity by LRP1.
###end title 97
###begin p 98
Absence of LRP1 results in increased activation of TGFbeta signaling. This is accompanied by disruption of elastic layers, tortuous aortas and increased fibrosis similar to what is observed in Marfan and Marfan-like syndromes in which the genes for fibrillin-1 or TGFbeta receptors are defective. Loss of LRP1 expression leads to increased expression of PDGF receptors. LRP1 also controls PDGFRbeta signaling and trafficking through an independent mechanism, and absence of LRP1 promotes VSMC proliferation and severe atherosclerosis. Rosiglitazone blocks TGFbeta signaling upstream of PDGFR, which is inhibited by Gleevec. Both drugs are thus effective in reducing arterial wall thickening and atherosclerosis, which are induced by increased PDGFR signaling.
###end p 98
###begin p 99
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 99
###begin p 100
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from, Fondation pour la Recherche Medicale, Fondation de France, Conseil Scientifique de l'Universite Louis Pasteur de Strasbourg, the National Institutes of Health (HL20948, HL63762, NS43408), and the Perot Family Foundation. J.H. is an Established Investigator of the American Heart Association and Parke-Davis and is the recipient of a Wolfgang-Paul Award from the Humboldt Foundation. None of the sponsors has placed any restrictions on the work or its publication.
###end p 100

